SG136119A1 - Pregabalin composition - Google Patents

Pregabalin composition

Info

Publication number
SG136119A1
SG136119A1 SG200705273-1A SG2007052731A SG136119A1 SG 136119 A1 SG136119 A1 SG 136119A1 SG 2007052731 A SG2007052731 A SG 2007052731A SG 136119 A1 SG136119 A1 SG 136119A1
Authority
SG
Singapore
Prior art keywords
pregabalin
composition
pregabalin composition
Prior art date
Application number
SG200705273-1A
Other languages
English (en)
Inventor
Michael Schneider
Hans Richard Meyer-Wonnay
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34486238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG136119(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of SG136119A1 publication Critical patent/SG136119A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG200705273-1A 2003-12-18 2004-12-06 Pregabalin composition SG136119A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03029117A EP1543831A1 (fr) 2003-12-18 2003-12-18 Composition de pregabaline

Publications (1)

Publication Number Publication Date
SG136119A1 true SG136119A1 (en) 2007-10-29

Family

ID=34486238

Family Applications (2)

Application Number Title Priority Date Filing Date
SG200705273-1A SG136119A1 (en) 2003-12-18 2004-12-06 Pregabalin composition
SG200803603-0A SG143257A1 (en) 2003-12-18 2004-12-06 Pregabalin composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG200803603-0A SG143257A1 (en) 2003-12-18 2004-12-06 Pregabalin composition

Country Status (17)

Country Link
US (1) US20050171203A1 (fr)
EP (2) EP1543831A1 (fr)
JP (1) JP2007514728A (fr)
KR (1) KR100841893B1 (fr)
CN (1) CN1893938A (fr)
AU (1) AU2004308747A1 (fr)
BR (1) BRPI0417585A (fr)
CA (1) CA2549599A1 (fr)
IL (1) IL176129A0 (fr)
MX (1) MXPA06006811A (fr)
MY (1) MY143561A (fr)
NO (1) NO20063178L (fr)
RU (1) RU2352333C2 (fr)
SG (2) SG136119A1 (fr)
TW (1) TWI279230B (fr)
WO (1) WO2005063229A1 (fr)
ZA (1) ZA200604656B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
EP2246044A1 (fr) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Solutions pédiatriques de bêta-bloquants
WO2010150221A1 (fr) 2009-06-25 2010-12-29 Wockhardt Research Centre Compositions pharmaceutiques de prégabaline de saveur masquée
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EA017542B1 (ru) * 2011-05-24 2013-01-30 Плива Кроэйша Лтд. Стабильная фармацевтическая композиция, содержащая прегабалин, капсула, ее содержащая, способ получения и применение
EA020558B1 (ru) * 2012-03-20 2014-12-30 ООО "Эн.Си. ФАРМ" Фармацевтический состав, обладающий нейропротекторной, антиамнестической, антиоксидантной, противогипоксической, нейрометаболической, противоишемической активностью (варианты)
EP3038465B1 (fr) 2013-08-30 2021-10-06 Merck Sharp & Dohme Corp. Formulation pharmaceutique orale d'omarigliptine
GR1009462B (el) * 2017-10-05 2019-02-15 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Ποσιμο φαρμακευτικο διαλυμα με συγκαλυμμενη γευση
CN107998074A (zh) * 2017-12-13 2018-05-08 广州大光制药有限公司 普瑞巴林口服溶液及其制备方法
CN110693820A (zh) * 2018-07-10 2020-01-17 北京万全德众医药生物技术有限公司 普瑞巴林口服溶液及其制备方法
MX2021011550A (es) 2019-03-26 2021-10-26 Orion Corp Formulaciones de pregabalina y uso de las mismas.
CN112107537A (zh) * 2019-06-19 2020-12-22 北京万全德众医药生物技术有限公司 一种普瑞巴林口服溶液及其制备方法
CN111855828B (zh) * 2020-02-28 2022-07-01 中国人民解放军军事科学院军事医学研究院 一种同时测定普瑞巴林以及羟苯酯类抑菌剂含量的方法
CN113616591B (zh) * 2021-09-03 2023-05-23 贝克诺顿(浙江)制药有限公司 一种普瑞巴林口服溶液及制备方法
GB2624861A (en) 2022-11-28 2024-06-05 Orbit Pharma Ltd Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5616793A (en) * 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) * 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
TR200003800T2 (tr) * 1998-06-22 2001-06-21 American Biogenetic Sciences, Inc. Migrenin tedavisi ve önlenmesinde valproik asit analoğu kullanımı
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
EP1250311B1 (fr) * 2000-01-27 2004-03-17 Warner-Lambert Company Synthese asymetrique de pregabaline
OA12604A (en) * 2001-05-25 2006-06-08 Warner Lambert Co Liquid pharmaceutical composition.
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2003222033A1 (en) * 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof

Also Published As

Publication number Publication date
TWI279230B (en) 2007-04-21
MY143561A (en) 2011-05-31
NO20063178L (no) 2006-06-19
CN1893938A (zh) 2007-01-10
BRPI0417585A (pt) 2007-03-13
JP2007514728A (ja) 2007-06-07
SG143257A1 (en) 2008-06-27
RU2006120946A (ru) 2008-01-27
TW200520751A (en) 2005-07-01
EP1543831A1 (fr) 2005-06-22
KR100841893B1 (ko) 2008-06-26
MXPA06006811A (es) 2006-08-23
US20050171203A1 (en) 2005-08-04
CA2549599A1 (fr) 2005-07-14
WO2005063229A1 (fr) 2005-07-14
KR20060103336A (ko) 2006-09-28
IL176129A0 (en) 2006-10-05
EP1722773A1 (fr) 2006-11-22
AU2004308747A1 (en) 2005-07-14
RU2352333C2 (ru) 2009-04-20
ZA200604656B (en) 2007-10-31

Similar Documents

Publication Publication Date Title
ZA200604656B (en) Pregabalin composition
GB0305941D0 (en) Composition
GB0302738D0 (en) Composition
GB0324918D0 (en) Composition
GB0203421D0 (en) Composition
GB0203280D0 (en) Anti-glycolytic composition
GB0324897D0 (en) Composition
GB0318824D0 (en) Novel composition
HK1087034A1 (en) Actacid composition
GB0322033D0 (en) Composition
GB0305790D0 (en) Novel Composition
MY145151A (en) Composition
HK1082517A1 (en) Oil-barrier composition
EP1495751A4 (fr) Composition de colorant capillaire
GB0309317D0 (en) Composition
GB0306312D0 (en) Composition
GB0324295D0 (en) Composition
GB0301869D0 (en) Composition
GB0326815D0 (en) Composition
GB0203616D0 (en) Composition
GB0324168D0 (en) Composition II
GB0323203D0 (en) Composition II
GB0320018D0 (en) Composition
GB0308260D0 (en) Composition
GB0320562D0 (en) Composition